Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Both compounds appear in exercise mimetic research, often as complementary tools
Ongoing monitoring: Periodic reassessment during extended protocols tracks both benefits and potential concerns
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
Researchers designing comparative protocols should treat the two compounds as related but mechanistically distinct tools rather than a single compound at different potencies
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
